NCT00073983View on ClinicalTrials.gov

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

December 31, 2010

Conditions

Sarcoma

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

pegfilgrastim

DRUG

docetaxel

DRUG

gemcitabine hydrochloride

GENETIC

microarray analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacokinetic study

All Listed Sponsors

lead

Sarcoma Alliance for Research through Collaboration

OTHER

NCT00073983 - Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma | Biotech Hunter | Biotech Hunter